92 related articles for article (PubMed ID: 27037661)
21. Rituximab as first choice for patients with refractory rheumatoid arthritis: cost-effectiveness analysis in Iran based on a systematic review and meta-analysis.
Ahmadiani S; Nikfar S; Karimi S; Jamshidi AR; Akbari-Sari A; Kebriaeezadeh A
Rheumatol Int; 2016 Sep; 36(9):1291-300. PubMed ID: 27136919
[TBL] [Abstract][Full Text] [Related]
22. Genetic prediction of the effectiveness of biologics for psoriasis treatment.
Nishikawa R; Nagai H; Bito T; Ikeda T; Horikawa T; Adachi A; Matsubara T; Nishigori C
J Dermatol; 2016 Nov; 43(11):1273-1277. PubMed ID: 27129929
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study.
Asahina A; Torii H; Ohtsuki M; Tokimoto T; Hase H; Tsuchiya T; Shinmura Y; Reyes Servin O; Nakagawa H
J Dermatol; 2016 Nov; 43(11):1257-1266. PubMed ID: 27129439
[TBL] [Abstract][Full Text] [Related]
24. Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab.
Vastesaeger N; Kutzbach AG; Amital H; Pavelka K; Lazaro MA; Moots RJ; Wollenhaupt J; Zerbini CA; Louw I; Combe B; Beaulieu A; Schulze-Koops H; Dasgupta B; Fu B; Huyck S; Weng HH; Govoni M; Durez P
Rheumatology (Oxford); 2016 Aug; 55(8):1466-76. PubMed ID: 27114562
[TBL] [Abstract][Full Text] [Related]
25. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
Curtis JR; Xie F; Yun H; Bernatsky S; Winthrop KL
Ann Rheum Dis; 2016 Oct; 75(10):1843-7. PubMed ID: 27113415
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.
Arakawa A; Ruzicka T; Prinz JC
JAMA Dermatol; 2016 Jul; 152(7):825-8. PubMed ID: 27096382
[TBL] [Abstract][Full Text] [Related]
27. Humira: the impending patent battles over adalimumab biosimilars.
Norman P
Pharm Pat Anal; 2016 May; 5(3):141-5. PubMed ID: 27087201
[TBL] [Abstract][Full Text] [Related]
28. Nail Psoriasis: A Review of Treatment Options.
Pasch MC
Drugs; 2016 Apr; 76(6):675-705. PubMed ID: 27041288
[TBL] [Abstract][Full Text] [Related]
29. Inclusion and exclusion criteria in phase III trials with systemic agents in psoriasis: the external validity of drug development.
Kirsten N; Bulai Livideanu C; Richard MA; Konstantinou MP; Khemis A; Balluteaud C; Goujon C; Beylot-Barry M; Paul C;
Br J Dermatol; 2016 Sep; 175(3):636-8. PubMed ID: 27038074
[No Abstract] [Full Text] [Related]
30. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study.
Yamasaki K; Nakagawa H; Kubo Y; Ootaki K;
Br J Dermatol; 2017 Mar; 176(3):741-751. PubMed ID: 27106510
[TBL] [Abstract][Full Text] [Related]
31. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3).
Blauvelt A; Papp KA; Lebwohl MG; Green LJ; Hsu S; Bhatt V; Rastogi S; Pillai R; Israel R
J Am Acad Dermatol; 2017 Aug; 77(2):372-374. PubMed ID: 28711089
[No Abstract] [Full Text] [Related]
32. Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.
Attia A; Abushouk AI; Ahmed H; Gadelkarim M; Elgebaly A; Hassan Z; Abdel-Daim MM; Negida A
Clin Drug Investig; 2017 May; 37(5):439-451. PubMed ID: 28197901
[TBL] [Abstract][Full Text] [Related]
33. Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases.
Nirula A; Nilsen J; Klekotka P; Kricorian G; Erondu N; Towne JE; Russell CB; Martin DA; Budelsky AL
Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii43-ii55. PubMed ID: 27856660
[TBL] [Abstract][Full Text] [Related]
34. Brodalumab: First Global Approval.
Greig SL
Drugs; 2016 Sep; 76(14):1403-12. PubMed ID: 27577550
[TBL] [Abstract][Full Text] [Related]
35. Transitioning Between Brodalumab and Secukinumab in Moderate to Severe Psoriasis: An Early Look.
Vender RB
J Drugs Dermatol; 2016 Aug; 15(8):941-3. PubMed ID: 27537993
[TBL] [Abstract][Full Text] [Related]
36. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
[TBL] [Abstract][Full Text] [Related]
37. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A.
Liu L; Lu J; Allan BW; Tang Y; Tetreault J; Chow CK; Barmettler B; Nelson J; Bina H; Huang L; Wroblewski VJ; Kikly K
J Inflamm Res; 2016; 9():39-50. PubMed ID: 27143947
[TBL] [Abstract][Full Text] [Related]
38. Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry.
Harrold LR; Reed GW; Karki C; Magner R; Shewade A; John A; Kremer JM; Greenberg JD
Arthritis Care Res (Hoboken); 2016 Dec; 68(12):1888-1893. PubMed ID: 27111064
[TBL] [Abstract][Full Text] [Related]
39. Rheumatoid arthritis: RA-BEACON illuminates baricitinib.
Ummarino D
Nat Rev Rheumatol; 2016 Jun; 12(6):313. PubMed ID: 27080693
[No Abstract] [Full Text] [Related]
40. Ultrasound-detected joint inflammation and B cell count: related variables for rituximab-treated RA patients?
Valor L; Martínez-Estupiñán L; Janta I; Nieto JC; Ovalles-Bonilla JG; González-Fernández C; Del Rio T; Hernández-Flórez D; Monteagudo I; López-Longo FJ; Naredo E
Rheumatol Int; 2016 Jun; 36(6):793-7. PubMed ID: 27072348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
